Pagani O, Regan MM, Fleming GF, et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. SABCS 2017, GS4-02.
Intensiteit behandeling endeldarmkanker afgenomen
feb 2024 | Chirurgie, Endoscopie, Maag-darm-leveroncologie, Radiotherapie